Number of pages: 120 | Report Format: PDF | Published date: 15 May, 2020
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
The global biosimilars market was pegged at ~US$ 15.1 billion in 2021 and is expected to witness a CAGR of ~21.5% during the forecast period.
Market Fundamentals
Biosimilar products are used for treatment, cure, prevention, or diagnosis of several conditions such as diabetes, kidney diseases, autoimmune disorders, and various types of cancers. These are derived from living organisms, such as plant cells, animal cells, and microorganisms. Biosimilars are identical in terms of potency, purity, and safety. The minor difference between the reference product and biosimilar is the clinically inactive compounds used in the making of biosimilars whereas the active compound (API) remains the same. Major approved biosimilars include monoclonal antibodies, vaccines, and therapeutic proteins. The prices of biosimilars are decreasing by each year owning to market competition.
[47534224]
Market Dynamics
The global biosimilars market is mainly driven by their cost-effectiveness and rising prevalence of chronic diseases such as cancer, diabetes, and rheumatoid arthritis. Also, globally increasing geriatric population also fueling the market growth. An increasing number of pipeline products are playing a pivotal role in contributing to the market growth globally. Biosimilars are a generic versions of biological products. Although they have same potency and effectiveness as biological products take usually a longer time for Research and development as compared to other conventional products. The longer time required for development, complex manufacturing process, higher cost development, and stringent government regulations for biosimilars production are some of the factors hindering the market growth.
Market Ecosystem
The global biosimilars market has been analyzed from four perspectives: Products, Disease Indication, Manufacturing Type, and Region.
Biosimilars Market by Product
Based on the product, the biosimilars market has been segmented into recombinant glycosylated proteins (monoclonal antibodies, follitropin, and erythropoietin), recombinant peptides (calcitonin and glucagon), and recombinant non-glycosylated proteins (human growth hormone, insulin, interferons, and granulocyte colony-stimulating factor). The recombinant non-glycosylated proteins segment is segmented into human growth hormone, insulin, interferons, and granulocyte colony-stimulating factor. The recombinant non-glycosylated proteins segment is anticipated to hold the largest market share owing to high patient pool of chronic diseases, continuous introduction of new biosimilars and current trend for alternative medicine. For instance, in May 2022 US FDA-approved new biosimilars like Fylnetra (pegfilgrastim-pbbk), Alymsys (bevacizumab-maly) and Releuko (filgrastim-ayow) and many biosimilars that can be used to treat stomach cancer, breast cancer, colorectal cancer, and other diseases that can be used as novel treatment.
Biosimilars Market by Disease Indication
[345232]
Based on disease indication, the market has been segmented into infectious diseases, oncology, autoimmune diseases, growth hormone deficiency blood disorders, and others. The oncology segment held the largest market share owing to increasing prevalence of cancers, increasing R&D activities for cancer drugs and need for low-cost treatment for cancers. Also, regulatory authority for use of biosimilars for cancer treatment pushes the biosimilars market growth. The cost of cancer treatment is not affordable for everyone and rapidly becoming challenging. Oncology biosimilars are helping minimize the economic burden associated with cancer treatment.
Biosimilars Market by Manufacturing Type
Based on manufacturing type, the market has been segmented into in-house manufacturing and contract manufacturing. In-house manufacturing segment held the largest market share owing to factors such as involvement of lower manufacturing costs, and increasing preference for in-house production to ensure product quality and confidentiality of the manufacturing process.
Biosimilars Market by Region
Based on the region, the global biosimilars market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). Europe dominated the biosimilars market followed by Asia Pacific. The large share of Europe in the global market can be attributed to several factors such as rising incidence of infectious diseases, rising geriatric population, and the presence of prominent players in this region. The presence of biosimilars in European market has been stronger giving early bird advantage to the region. Also, it is reported that over the past decade, Europe has witnessed the highest number of biosimilar commercialization.
Competitive Landscape
Some of the prominent players operating in the global biosimilars market are Pfizer Inc., Sandoz International GmbH, Amgen Inc., Samsung Biologics., Biocon, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Celltrion Healthcare Co., Ltd., Mylan N.V., and STADA Arzneimittel AG among others.
Strategic Developments
|
Report Attribute |
Details |
|
Market size value in 2021 |
~US$ 15.1 billion |
|
Revenue forecast in 2030 |
~US$ 87.12 billion |
|
Growth Rate |
CAGR of ~21.5% from 2022 to 2030 |
|
Base year for estimation |
2021 |
|
Forecast period |
2022-2030 |
|
Segments covered |
Product, Disease Indication, Manufacturing Type |
|
Regional scope |
North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
The global biosimilars Market was anticipated to clock ~US$ 15.1 billion in 2021
The biosimilars market is projected to reach ~US$ 87.12 billion by 2030
The global biosimilars market is mainly driven by their cost-effectiveness.
Pfizer Inc, Sandoz International GmbH, Amgen Inc, Samsung Biologics, Biocon, Teva Pharmaceutical Industries Ltd, Eli Lilly and Company, Celltrion Healthcare Co., Ltd, Mylan N.V., STADA Arzneimittel AG
The growth rate of biosimilars market is CAGR of ~21.5% between 2022-2030
Europe dominated the biosimilars market followed by Asia-Pacific